Opicapone in Parkinson’s Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: To evaluate opicapone (OPC) when used in everyday clinical practice conditions to treat Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC proved to…Predictive factors of LCIG infusion therapy adherence – a single-center study of 103 consecutive LCIG patients
Objective: The objectives of this study were to find predictive factors for early dropout from levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD)…Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson’s Disease
Objective: We aimed to investigate the plasma short-chain fatty acids (SCFAs) in multiple system atrophy (MSA) patients and to identify the potential differential diagnostic ability.…Predictors of survival in Progressive Supranuclear Palsy in a Tunisian cohort
Objective: To investigate survival and its determinants in a Tunisian cohort of Progressive Supranuclear Palsy (PSP). Background: PSP is a neurodegenerative tauopathy characterized by faster…TELEMONITORING OF THE ORAL HEALTH OF PARKINSONIANS DURING THE NEW CORONAVIRUS PANDEMIC
Objective: To Promote telemonitoring of the oral health of people with Parkinson disease in times of Covid-19. Background: Among the most affected population by Covid-19…COMPARISON OF FREQUENCY, CLINICAL PROFILE AND ETIOLOGIES OF PARKINSONISM IN 2008 AND 10 YEARS LATER AT THE NEUROLOGY DEPARTMENT OF BEFELATANANA UNIVERSITY TEACHING HOSPITAL, ANTANANARIVO, MADAGASCAR
Objective: To compare the frequency, the clinical profile of parkinsonism and its etiologies in 2008 and 10 years later in our department. Background: Number of…Motor and non-motor effects of mevidalen in Lewy Body Dementia as measured by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Objective: To assess the motor and non-motor effects of mevidalen in patients with Lewy Body Dementia (LBD) as measured by the MDS-UPDRS. Background: Mevidalen is…Rapidly progressive dementia after MRI-guided Focused Ultrasound (MR-FUS)
Objective: To present a Parkinson´s Disease (PD) patient who presented a rapidly progressive dementia after MR-FUS therapy. Background: MR-FUS thalamotomy is used for unilateral essential…Shannon entropy: a novel tool for assessing pentagon drawing in Parkinson’s disease
Objective: We used a digitizing tablet during PCT as a potential tool for assessing early cognitive deficits in PD yet without major cognitive impairment. We…Cognitive-driven ADL impairment as a predictor for PDD
Objective: To evaluate whether Parkinson’s disease (PD) patients with mild activity of daily living (ADL) impairment are at higher risk for developing dementia (PDD). Background:…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.